Event Brief
May 14, 2026 at 1:03 PM ET
Biogen to advance tau-targeting Alzheimer drug to Phase 3
By The BriefBrief
Biogen said it will move its tau-targeting Alzheimer’s drug into Phase 3 despite disappointing mid-stage results.
WHO: Biogen
WHAT: Biogen said it will advance an experimental tau-targeting Alzheimer’s drug to Phase 3 testing despite disappointing mid-stage trial data.
WHEN: May 14, 2026 at 12:10 PM ET
WHERE: Location not specified
WHY: Signals suggested the treatment decreases tau levels and slows cognitive decline, particularly at the lowest dose.
Reporting from 1 identified publisher for this event.
View all 1 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Mortgage rates tick lower to 6.36%
Us
May 14, 2026 at 1:03 PM ET
Teacher’s killing fuels scrutiny of Roy Cooper
Roy Cooper
May 14, 2026 at 1:03 PM ET
Dell launches 14S and 16S to replace old Plus models
Dell
May 14, 2026 at 1:03 PM ET
Musk China trip prompts apology from his lawyer
Openai
May 14, 2026 at 1:03 PM ET
Page 18767 of 21435
Same format. Every time.
Continue reading — sign in or create a free account with
